NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Why Morningstar thinks Anthropic is worth $1.7 trillion
A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,267.80 | 104.40 | 1.14% |
| CAC 40 | 8,233.30 | 94.30 | 1.16% |
| DAX 40 | 26,267.19 | 446.83 | 1.73% |
| Dow JONES (US) | 52,389.75 | 1,104.02 | 2.15% |
| FTSE 100 | 10,782.87 | 108.93 | 1.02% |
| HKSE | 24,540.81 | 91.86 | 0.38% |
| NASDAQ | 25,253.14 | 673.71 | 2.74% |
| Nikkei 225 | 60,459.58 | 1,684.08 | 2.87% |
| NZX 50 Index | 14,167.41 | 193.79 | 1.39% |
| S&P 500 | 7,549.94 | 173.08 | 2.35% |
| S&P/ASX 200 | 9,129.00 | 99.30 | 1.10% |
| SSE Composite Index | 3,663.72 | 2.93 | 0.08% |